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Abstract
Background—African Americans (AA) in the United States have higher rates of colon cancer
(CC) mortality than other races. This study examines the use of oxaliplatin, a novel
chemotherapeutic agent approved in 2004, among AA and Caucasian Americans (CA) patients
with stage III colon cancer to understand whether differential receipt or differential effectiveness
of the drug may explain the racial disparity in CC mortality.
Methods—We conducted a population-based retrospective cohort study of stage III CC patients
age 65 and older treated from 2004 through 2006 who initiated chemotherapy within 90 days of
surgical resection (N=1162) using Surveillance, Epidemiology and End Results (SEER)-Medicare
data. Patients receiving oxaliplatin (n=477) were compared with those receiving 5-Fluorouracil (5-
FU) without oxaliplatin (n=685). We estimated prevalence ratios (PR) and hazard ratios (HR)
using multivariable binomial regression and Cox models to evaluate racial differences in
oxaliplatin receipt and survival.
Results—AAs were as likely as CAs to receive oxaliplatin (40.5 vs. 41.1%; PR=0.90; CI:
0.71-1.13). Oxaliplatin was associated with lower mortality compared with 5-FU (HR=0.76; CI:
0.58-1.00). This benefit appeared stronger among AAs (HR=0.31; CI:0.09-1.05) than CAs
(HR=0.80; CI:0.60-1.06).
Conclusions—In Medicare-insured patients receiving chemotherapy, we observed no
meaningful racial disparities in receipt of oxaliplatin and, among those receiving it, potentially
better survival among AAs. Differential receipt and effectiveness of oxaliplatin-containing
regimens does not appear to contribute to the previously documented racial disparities in colon
cancer survival. Understanding reasons for potentially enhanced effectiveness among AAs may
inform efforts to resolve racial disparities in colon cancer outcomes.
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BACKGROUND
Colorectal cancer is the third most common cancer in the United States, with an age-
adjusted incidence rate of 41.1 cases per 100,000 people per year1. In 2011, over 141,000
new cases are expected, approximately a third of which will be diagnosed as stage III.
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Colorectal cancer is a leading cause of cancer mortality, with more than 51,000 people
expected to die from it this year. Racial disparities in mortality are substantial – African
Americans (AA) are approximately 44% more likely to die from colon cancer than
Caucasian Americans (CA)2. Thanks to improved screening and the introduction of several
innovative treatments, colon cancer (CC) mortality has declined since the 1980’s, but has
not declined equivalently among races3,4. This disparity may result from differential
dissemination of the innovative treatments in different subpopulations, or differential
effectiveness among them.
Many factors contribute to racial differences in access to care, care utilization, and
outcomes. For example, AA mistrust of physicians, lack of a regular source of care, and
poor continuity of care have been associated with lower use of preventive services, delays in
treatment, and lower quality of follow-up, and subsequently worse outcomes5,6,7,8,9,10,11,12.
In sum, real-world care may fall short of optimal patient management. Adjusting for
socioeconomic status (SES) may account for some of the differences attributed to race;
however, in studies controlling for these factors, the mortality gap between races
remains13,14. After SES adjustment, AA patients are less likely to receive adjuvant
chemotherapy for resectable colorectal cancer than CAs15,16,17, suggesting that there may be
disparities in the use of the more effective and/or innovative drugs. However, we do not
have good data on racial differences in the receipt of specific chemotherapies among treated
CC patients.
Innovative therapies might also have a heterogeneous effect on outcome in different races,
as there is substantial evidence that an individual’s genetic makeup may affect the
effectiveness and toxicity of systemic chemotherapy (pharmacogenetics). In colorectal
cancer, there are many examples of genotypic association with chemotherapy outcomes such
as UGT1A1*28 allele and irinotecan toxicity, and thymidylate synthase TSER
polymorphism and 5-FU benefit18,19,20. New evidence suggests that chemotherapy, and
specifically oxaliplatin, may cause fewer side effects in AAs21,22,23, which could lead to
better drug delivery, adherence and persistence, and ultimately greater effectiveness.
However, this would be expected to improve mortality in AAs and can therefore not explain
the observed mortality gap.
The standard of care for stage III CC is surgical resection, followed by chemotherapy24. In
2004, oxaliplatin was FDA-approved for stage III CC and, used in combination therapy with
5-Fluorouracil (5FU) (i.e., the FOLFOX regimen), replaced 5-FU alone, the prior standard
adjuvant therapy. At that time, FOLFOX was shown to improve disease-free survival over
5-FU (rate of 72.2% vs. 65.3%)25 and subsequently to improve survival in patients with
stage III CC (HR=0.86, 95% CI, 0.66, 1.11)26. However, potential racial differences in
effectiveness were not adequately examined in the clinical trials, which had much less
racially diverse populations than the general CC population. Moreover, differential access to
care cannot effectively be examined in randomized clinical trials (RCTs).
To examine whether the racial disparity in CC mortality can be partially explained by either
access to innovative treatments or differential treatment effectiveness, this study evaluated a
heterogeneous population-based sample27 for racial differences in the use and comparative
effectiveness of FOLFOX, a combination chemotherapy including the novel drug
oxaliplatin.
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A population-based retrospective cohort was drawn from the Surveillance, Epidemiology
and End Results (SEER)- linked-Medicare data, which have been described extensively
elsewhere28. Briefly, the National Cancer Institute’s (NCI) SEER program collects clinical
and demographic data on incident cancers and covers approximately 28% of the U.S.
population. Medicare is U.S. public health insurance that insures approximately 97% of
those aged 65 and older in the U.S. The linkage of Medicare claims with SEER provides
critical information on patient demographics, cancer characteristics, health care utilization,
and comorbidities, and has been used extensively to study cancer patterns of care and
outcomes29.
Patient Population and Sample
The study cohort included individuals diagnosed with primary stage III CC who were first
treated between January 1, 2004 and December 31, 2006, the years immediately following
determination of oxaliplatin efficacy and FDA approval. Included patients received surgical
resection (colectomy or resection of colon or large intestine) within 180 days of diagnosis
and initiated the first course of chemotherapy within 90 days of surgery. All patients
received one of the two chemotherapies of interest: 5-FU without oxaliplatin (the previously
standard therapy) or an oxaliplatin-containing regimen (the innovative therapy). Additional
exclusion criteria (Figure 1) include: Incomplete claims or HMO coverage during the 12
months pre- and post-diagnosis or until death, to ensure attainment of treatment and
procedure claims; age younger than 65, as these individuals may be systematically different
or have incomplete claims as a function of Medicare eligibility requirements; diagnosis at
autopsy; appendix or rectosigmoid junction cancer; death within 30 days of surgery, as these
patients are unlikely to have received chemotherapy due to fragile health status; and race
other than CA or AA. The sample was restricted to patients from SEER registry regions with
5% or greater AA populations.
Definition of Cohorts
FOLFOX was defined as the presence of an oxaliplatin claim, since oxaliplatin is the
defining drug of the FOLFOX regimen and the innovative treatment of interest. The referent
treatment group received 5-FU, the prior standard for chemotherapy, and had no claims for
oxaliplatin. Those receiving other treatments with 5-FU (e.g. irinotecan) were included in
the referent group. An exposure window of 150 days from diagnosis was used to ensure
inclusion of all patients treated according to American Society of Clinical Oncology /
National Comprehensive Cancer Network quality standards. These guidelines recommend
administering adjuvant chemotherapy within 120 days of diagnosis for stage III CC30, and a
30 day “buffer” was added because SEER-Medicare does not contain the specific diagnosis
date (month/year only). Patients who received chemotherapy before surgery are likely stage
IV patients misclassified as stage III and were not included.
Mortality Follow-up and Covariates
Mortality follow-up started 90 days after surgery irrespective of when chemotherapy was
initiated. Date of death was ascertained from Medicare data, which is drawn from the U.S.
Social Security Administration, and was available in these data through December 31, 2006.
Race, the primary covariate of interest, along with other adjustment variables of age, sex,
urbanity, tumor grade, tumor substage, site of tumor, SEER registry, median income, and
radiation were obtained through SEER data. Race is considered an accurate variable in
SEER for AA and CA31. Chemotherapy, comorbidities and procedures were identified
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through Health Care Procedure Classification Codes (HCPCS), National drug codes (NDC),
Current Procedural Terminology (CPT) and ICD-9 codes in Medicare claims. Comorbidity
was adjusted for using the NCI-Combined Comorbidity Index, adapted from the SEER-
Medicare program32. This index was constructed using claims for the 12 months prior to
diagnosis33.
Analytic methods
Frequency tables and comparisons of covariates by treatment group and race were examined
as part of a descriptive analysis. Treatment proportions were compared to examine whether
AAs were as likely to receive oxaliplatin-based treatments as CAs. Crude and adjusted
binomial regression models were constructed to estimate prevalence ratios (PR) for
treatment assignment by race. Crude all-cause 3-year mortality was computed for patients
who had 3 or more years of follow-up or who died during the study time period to compare
risk of death between CAs and AAs. Cox models including all patients were used to
estimate crude and adjusted hazard ratios (HR) for overall mortality comparing AAs vs. CAs
and the initiation of FOLFOX vs. 5-FU regimens in an intent-to-treat approach based on all
available follow-up information. HR estimates for race as a predictor of death were then
compared, first unadjusted and then adjusted for oxaliplatin receipt. Cox models were
constructed in a subgroup analysis to examine differences in oxaliplatin effectiveness
between races. We measured the interaction of race and oxaliplatin on mortality using the
interaction contrast ratio (ICR)34,35, as the additive scale (joint effects) is most appropriate
when investigating biologic interactions and for clinical decision making36. Proportional
hazard assumptions were tested and confirmed using log likelihood tests and graphical
methods. To compare survival by race among those who received oxaliplatin, adjusted
Kaplan-Meier survival curves were generated. All analyses were performed using SAS
(version 9.2.; SAS Institute, Cary, NC).
Directed Acyclic Graph (DAG) methodology was used to identify potential confounders37.
Independent variables identified as important for adjustment in all models were age, sex,
urbanity, tumor grade, tumor substage, site of tumor, SEER registry, median income,
radiation, and NCI-Combined Comorbidity Index. Race, the primary independent variable of
interest in treatment receipt models, and year of treatment were considered important
confounders in analyses looking at the association between treatment and mortality.
Sensitivity analyses
Three sensitivity analyses were performed to test assumptions and selection of the study
cohort. First, inclusion criteria were expanded to include all races, and AAs were compared
with all other races instead of CAs only. Second, we examined the timing of surgery after
diagnosis by restricting the cohorts to surgery within 90 days after diagnosis instead of 180
days. Some patients with surgery more than 90 days after diagnosis could have been
erroneously categorized as stage III when in fact they already have metastatic disease. Third,
to examine potential biases in the manner that follow-up time was calculated in Cox models,
analyses were rerun with an origin of 30 days after the first date of 5-FU receipt instead of
using 90 days after surgery.
RESULTS
Study population and oxaliplatin use
In descriptive analyses (Table 1), treatment groups were similar. Those receiving oxaliplatin
(n=477) were slightly younger, had less comorbidity, and were in higher income brackets
that those receiving 5-FU without oxaliplatin (n=685). Oxaliplatin use was greater among
those diagnosed in 2005 than in 2004 (56.4% vs. 43.6%) as the innovation diffused into
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practice. AAs comprised 10% (n=116) of the study population. There was variation in racial
distribution among SEER registries; additionally, AAs were more likely to be female and
were generally in a lower income bracket than CAs. AAs were as likely as CAs to receive
oxaliplatin (40.5% vs. 41.1%; adjusted PR, 0.90, 95% confidence interval [CI], 0.71-1.13).
Mortality and oxaliplatin effectiveness
Overall mortality among all cohort subjects was 28.8% (n=335) over a mean follow-up of
2.4 years. Oxaliplatin was protective in terms of lower mortality compared to 5-FU
regimens, with adjusted HR, 95% CI of 0.76, 0.58-1.00.
Mortality among AA patients with stage III CC who were treated with chemotherapy tended
to be lower than that of CA patients, with an adjusted overall HR, 95% CI of 0.84, 0.56-1.28
(Table 2) and three-year mortality risk of 32.5% vs. 39.3%, p=0.34. HR estimates did not
appreciably change when adjusted for receipt of oxaliplatin (adjusted HR, 0.85, 95%CI,
0.56-1.28).
Fewer than 11 of 41 AAs on Oxaliplatin died, compared with 23 of 69 AAs who died on 5-
FU (the exact number is suppressed due to SEER-Medicare confidentiality requirements).
The protective effect from oxaliplatin compared with 5-FU was more profound in AA than
CAs: adjusted HR, 95% CI estimates were 0.83, 0.62-1.09 for CAs and 0.31, 0.12-0.82 for
AAs (Figures 2, 3). The formal examination of the race-oxaliplatin interaction on mortality
(assessment of joint effects) also demonstrates a greater benefit of oxaliplatin among AAs
(Table 3). The absolute difference in the benefit between races was estimated as 57% of the
hazard rate among the CAs receiving 5-FU (ICR, −0.57, 95% CI, −1.19 to 0.05).
Sensitivity analyses
To assess if the inclusion of other races with CAs would change or bias the study results, a
sensitivity analysis compared AAs (n=116) with CAs and all other races (n=1098), rather
than with CAs alone (n=1046). The associations between race and mortality and between
race and oxaliplatin receipt were essentially unchanged. The small sample size of other races
(n=52 not CA or AA) precluded this group’s independent examination in comparison to
AAs. Narrowing the timing of surgery after diagnosis from 180 to 90 days excluded 42
additional patients but estimates were equal in magnitude to the main analysis. Similarly,
using an origin of 30 days after the first date of 5-FU receipt instead of 90 days after surgery
excluded 84 patients but yielded no meaningful change in mortality HRs.
DISCUSSION
In this study examining whether racial disparities in CC mortality may be partly attributed to
differential receipt or effectiveness of oxaliplatin, we found that, among older individuals
with resected stage III disease, not only were AAs and CAs equally likely to receive
oxaliplatin, but oxaliplatin unexpectedly appeared to be more effective among AAs than
CAs. Overall, oxaliplatin-treated patients had lower mortality than patients treated with non-
oxaliplatin regimens, a finding consistent with RCTs and recent observational comparative
effectiveness research results38. While the study findings do not explain racial disparities in
CC mortality, the results overall are meaningful in our understanding of CC treatment and
racial disparities.
Differential mortality
Our finding that AA patients experienced slightly lower mortality than CAs is contrary to
the findings of other studies39,40,41. This may be due to the equal access to overall medical
coverage experienced by those in the study, who were all Medicare subscribers. It could also
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be that racial minorities enter at a later stage in the cancer care continuum42, but that once
engaged in the health care system, any differences in the care they receive have little effect
on mortality. The resources made available through Medicare participation to individuals in
this study, who have accessed the health care system and been diagnosed with cancer, may
have essentially eliminated the disparity in access to care after diagnosis, and thus
eliminated the disparity in mortality. Indeed, in a study of stage III colorectal cancer patients
treated at Veterans Affairs hospitals where all patients have equal access to medical care,
there were no racial differences in receipt of appropriate colorectal cancer therapies and
minimal racial differences in all-cause mortality43. As it pertains to differential access
among individuals not covered by Medicare, our data offer little utility; the SEER-Medicare
data reflect a population with health insurance, although distance/access to providers, co-
payments and deductibles can still be substantial barriers to receiving care among insured
populations. This study used census-level measures of SES, which are limited in their ability
to remove all SES-related confounding.
Possible racial differences in oxaliplatin effectiveness
The relatively equal receipt of oxaliplatin between races coupled with the better survival of
AAs suggests that there could be differences in oxaliplatin effectiveness based on race. This
is meaningful, given that the proportion of minorities in RCTs of oxaliplatin efficacy were
substantially smaller than the overall population with CC, as well as younger and healthier,
and that seminal reports of oxaliplatin efficacy have not reported race-specific
outcomes44,45,46. Race-stratified HRs as well as the analysis of joint effects showed that
oxaliplatin was potentially more protective among AAs as compared to CAs. This is a novel
finding that has generally not been seen in clinical trials, although other possible differences
in oxaliplatin effectiveness have been described. Within a subgroup analysis of a large RCT
comparing bolus irinotecan/fluorouracil (FU)/leucovorin (LV) (IFL) with oxaliplatin/
infusional FU/LV (FOLFOX) and bolus irinotecan and oxaliplatin (IROX)47, AAs were
found to be less likely to experience severe adverse events from chemotherapy compared
with CAs. However, this trial also found that the response rate to oxaliplatin was lower
among AAs compared with CAs, which is contrary to our finding. If AAs do have fewer
side-effects during treatment, it is possible that they have greater treatment completion rates
than CAs when taking oxaliplatin and are better able to maintain dose intensity and dose
density. If true, this improved drug delivery might result in better outcomes in clinical
practice.
Alternate explanations
Another plausible reason for a more pronounced mortality reduction in AAs receiving
oxaliplatin is channeling away from oxaliplatin in frail patients, (i.e. unmeasured
confounding), which could be stronger in AAs than CAs. This channeling could be due to
different prescribing or different decision-making among AAs compared with CAs, which
has been shown in previous studies48,49. Clinicians may be less likely to use a more
aggressive treatment such as oxaliplatin among patients who are sicker and thus potentially
more likely to experience the risks of treatment without its prospective benefit50,51. It is
possible that AAs in this study were sicker than CAs but that we were unable to see this
difference in the dataset used, because health status measures such as frailty and functional
status are not available in Medicare data. We did adjust for comorbidities found within the
12 months before cancer diagnosis, but differences in health status may still exist and yield
residual confounding, which could be problematic when looking at mortality.
It is also possible that by removing those not treated with any chemotherapy, we may have
excluded the patients who contribute to the gap in mortality between races. A similar
proportion of both races were excluded for not receiving any chemotherapy within 90 days
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of surgery, however, so this is unlikely. As in all analyses, chance could also account for our
results. In our final patient population, there were small numbers of AAs who died while on
oxaliplatin, which limited our ability to construct precise estimates; future studies with more
events are warranted.
Limitations and sensitivity analyses
Use of claims data has potential limitations that have been well described52,53,54. We
employed state-of-the art methods to minimize these acknowledged biases. In the overall
analyses, we excluded races other than AA or CA, and then performed sensitivity analyses
which suggested that results would not appreciably differ if we had compared AAs to all
races. In SEER, there is an estimated 80% concordance with diagnosis date and timing of
claims for CC55 but only month and year of diagnosis are provided; therefore, index dates
must be estimated. We built a time buffer to take this into account by adding 30 days to the
recommended treatment window and using the first day of the previous month as an index
date for finding surgeries and chemotherapies. We also took a conservative approach for
inclusion, allowing patients who received surgery up to 180 days after diagnosis in the
study. Sensitivity analyses suggest that results would be similar if surgery timing after
diagnosis was restricted to 90 days.
Because Medicare is estimated to have 75% sensitivity for picking up 5-FU56, we may have
missed a proportion of the referent group. To avoid missing a considerable proportion of
FOLFOX users, we used evidence of treatment with oxaliplatin to define our exposure
rather than requiring evidence of all medications in the FOLFOX regimen. Exposure
misclassification would be possible for those that started 5-FU toward the end of the 150-
day claims window defined by this study and started oxaliplatin after the 150 days window.
This misclassification is likely small and would tend to bias results toward the null. Within
the referent group, few patients were on other chemotherapeutic agents in addition to 5-FU:
5.8% received irinotecan and 1.2% received bevacizumab. Sensitivity analyses excluding
these patients from the referent group demonstrated no difference in findings (data not
shown).
To ensure comparability of our results with previous work, mortality follow-up began 90
days after surgery irrespective of when chemotherapy was initiated. All included patients
had started chemotherapy by this landmark. Primary results were essentially unchanged in
sensitivity analyses beginning follow-up closer to chemotherapy start (30 days after first
date of 5-FU).
Overall findings
This is the largest population-based study assessing race-specific channeling and
comparative effectiveness of oxaliplatin to-date. Our findings of potential heterogeneity of
effect in different races highlight the need for additional comparative effectiveness research
on these therapies57. Using the SEER-Medicare data set, we have been able to demonstrate
that oxaliplatin retains its effectiveness among an unselected group of elderly CC patients to
a similar degree as seen in clinical trials. Furthermore, we have shown that elderly AA colon
cancer patients, who are markedly underrepresented in clinical trials, derive as much if not
more benefit from the addition of oxaliplatin.
CONCLUSIONS
In Medicare-insured stage III colon cancer patients receiving chemotherapy, we observed no
meaningful racial disparities in receipt of oxaliplatin, the more effective treatment, and
potentially better survival among AAs. Differential receipt or effectiveness of oxaliplatin-
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containing regimens does not appear to contribute to previously reported racial disparities in
CC survival. Rather, our findings suggest that oxaliplatin may act more effectively in AAs,
although small numbers and other limitations require confirmatory research. This, combined
with new evidence that oxaliplatin effectiveness may vary with biological differences,
highlights the importance of future studies examining oxaliplatin effectiveness by race.
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Medicare-insured African Americans with stage III colon cancer are not less likely to
receive the novel recommended chemotherapy, oxaliplatin, than Caucasian Americans.
African Americans may even benefit more than Caucasian Americans from this
treatment.
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Figure 1. Selection of study population from SEER-Medicare data
* Percentages shown are the proportion within the racial group excluded based on each
selection criteria. CA=Caucasian American, AA=African American
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Figure 2. Effectiveness of Oxaliplatin over 5-FU in Preventing Mortality Stratified by Race*
* N= 1162; data ascertained via NCI SEER Registry and Medicare claims files.
** Adjusted for age, sex, urbanity, tumor grade, tumor substage, site of tumor, SEER
registry, median income, radiation, NCI-Combined Comorbidity Index, year of treatment.
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Figure 3. Comparison of Kaplan-Meier Survival by Race among Stage III Colon Cancer Patients
on Oxaliplatin
* N= 477; data ascertained via NCI SEER Registry and Medicare claims files.
** Adjusted for age, sex, urbanity, tumor grade, tumor substage, site of tumor, SEER
registry, median income, radiation, NCI-Combined Comorbidity Index, year of treatment.
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Table 2
Study Results: Comparison of Treatment Receipt and Mortality by Race and Chemotherapy (N=1162)
Crude Analysis Adjusted* Analysis
Comparison of treatment receipt PR 95% CI PR 95% CI
Received FOLFOX by race (AA vs. CA) 0.99 0.78, 1.24 0.90 0.71, 1.13
Comparison of mortality HR 95% CI HR 95% CI
Mortality by treatment (FOLFOX vs. 5-FU) 0.73 0.57, 0.93 0.76 0.58, 1.00
Mortality by race (AA vs. CA) 0.83 0.56, 1.22 0.84 0.56, 1.28
Mortality by race (AA vs. CA), treatment adjusted 0.83 0.57, 1.23 0.85 0.56, 1.28
*
Adjusted for age, sex, urbanity, tumor grade, tumor substage, site of tumor, SEER registry, median income, radiation, NCI-Combined
Comorbidity Index for all models; race, year of treatment for models looking at treatment and mortality.
PR=Prevalence Ratio, HR=Hazard Ratio, CI=Confidence Interval, CA=Caucasian American, AA=African American













Mack et al. Page 19
Table 3
Strata-Specific Estimates and Interaction of Treatment and Race (N=1162)
Stratified Individual/Joint effects
Exposure HR* 95% CI HR* 95% CI
Caucasian American
 5-FU without oxaliplatin 1.0 (referent) 1.0 (referent)
 Oxaliplatin 0.83 0.62 to 1.10 0.83 0.62 to 1.09
African American
 5-FU without oxaliplatin 1.0 (referent) 1.08 0.68 to 1.71
 Oxaliplatin 0.31 0.12 to 0.83 0.33 0.13 to 0.83
*
Adjusted for age, sex, urbanity, tumor grade, tumor substage, site of tumor, SEER registry, median income, radiation, NCI-Combined
Comorbidity Index and year of treatment.
HR=Hazard Ratio, CI=Confidence Interval
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